Structure-activity studies of 6-(tetrazolylalkyl)-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 1. Effects of stereochemistry, chain length, and chain substitution

Journal of Medicinal Chemistry

Volumn 39, Issue 11, 1996, Pages 2219-2231

  Ornstein, Paul L ^a   Arnold, M Brian ^a   Allen, Nancy K ^a   Bleisch, Thomas ^a   Borromeo, Peter S ^a   Lugar, Charles W ^a   Leander, J David ^a   Lodge, David ^a   Schoepp, Darryle D ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 PHOSPHONOMETHYLPIPECOLIC ACID; 6 [2 (1H TETRAZOL 5 YL)ETHYL] 1,2,3,4,4A,5,6,7,8,8A DECAHYDROISOQUINOLINE 3 CARBOXYLIC ACID; 6 CYANO 7 NITRO 2,3 QUINOXALINEDIONE; 6,7 DINITRO 2,3 QUINOXALINEDIONE; ALPHA AMINO 3 HYDROXY 5 METHYL 4 ISOXAZOLEPROPIONIC ACID; CARBOXYLIC ACID DERIVATIVE; ISOQUINOLINE DERIVATIVE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ARTICLE; BRAIN CORTEX; BRAIN PROTECTION; CELL MEMBRANE PERMEABILITY; CENTRAL NERVOUS SYSTEM; DRUG POTENCY; ENZYME ACTIVATION; NONHUMAN; SIGNAL TRANSDUCTION; STEREOCHEMISTRY; STRUCTURE ACTIVITY RELATION; SYNAPTIC TRANSMISSION;

ALPHA-AMINO-3-HYDROXY-5-METHYL-4-ISOXAZOLEPROPIONIC ACID; ANIMALS; CARBOXYLIC ACIDS; CEREBRAL CORTEX; ISOQUINOLINES; KAINIC ACID; KINETICS; MOLECULAR STRUCTURE; N-METHYLASPARTATE; PIPECOLIC ACIDS; RADIOLIGAND ASSAY; RATS; RECEPTORS, AMPA; STRUCTURE-ACTIVITY RELATIONSHIP; TETRAZOLES; TRITIUM;

EID: 0029946630     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950912p     Document Type: Article

References (51)

1. Collingridge, G. L.; Lester, R. A. Excitatory amino acid receptors in the vertebrate central nervous system. Pharmacol. Rev. 1989, 40, 143-210.
2. Cunningham, M. D.; Ferkany, J. W.; Enna, S. J. Excitatory amino acid receptors: a gallery of new targets for pharmacological intervention. Life Sci. 1994, 54, 135-148.
3. Schoepp, D. D.; Conn, P. J. Metabotropic glutamate receptors in brain function and pathology. Trends Pharmacol. Sci. 1993, 14, 13-20.
4. Pin, J.-P.; Duvoisin, R. The metabotropic glutamate receptors: structure and functions. Neuropharmacology 1995, 34, 1-26.
5. Honoré, T.; Davies, S. N.; Drejer, J.; Fletcher, E. J.; Jacobsen, P.; Lodge, D.; Nielsen, F. E. Quinoxalinediones: potent competitive non-NMDA glutamate receptor antagonists. Science 1988, 241, 701-703.
6. Sheardown, M. J.; Nielsen, E. Ø.; Hansen, A. J.; Jacobsen, P.; Honoré, T. 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(F)quinoxaline: a neuroprotectant for cerebral ischemia. Science 1990, 247, 571-574.
7. Smith, S. E.; Dürmüller, N.; Meldrum, B. S. The non-N-methyl-D-aspartate receptor antagonists, GYKI 52466 and NBQX are anticonvulsant in two animal models of reflex epilepsy. Eur. J. Pharmacol. 1991, 201, 179-183.
8. Yamaguchi, S.; Donevan, S. D.; Rogawski, M. A. Anticonvulsant activity of AMPA/kainate antagonists: comparison of GYKI 52466 and NBQX in maximal electroshock and chemoconvulsant models. Epilepsy Res. 1993, 15, 179-184.
9. Zarnowski, T.; Kleinrok, Z.; Turski, W. A.; Czuczwar, S. J. 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline enhances the protective activity of common antiepileptic drugs against maximal electroshock-induced seizures in mice. Neuropharmacology 1993, 32, 895-900.
10. Löscher, W.; Rundfeldt, C.; Honack, D. Low doses of NMDA receptor antagonists synergistically increase the anticonvulsant effect of the AMPA receptor antagonist NBQX in the kindling model of epilepsy. Eur. J. Neurosci. 1993, 5, 1545-1550.
11. Wrathall, J. R.; Choiniere, D.; Teng, Y. D. Dose-dependent reduction of tissue loss and functional impairment after spinal cord trauma with the AMPA/kainate antagonist NBQX. J. Neurosci. 1994, 14, 6598-6607.
12. McCulloch, J.; Glutamate receptor antagonists in cerebral ischemia. J. Neural Transm. [Suppl.] 1994, 43, 71-79.
13. Gill, R. The pharmacology of α-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate antagonists and their role in cerebral ischemia. Cerebrovasc. Brain Metab. Rev. 1994, 6, 225-256.
14. Xue, D.; Huang, Z.-G.; Barnes, K.; Lesiuk, H. J.; Smith, K. E.; Buchan, A. M. Delayed treatment with AMPA, but not NMDA, antagonists reduces neocortical infarction. J. Cerebr. Blood Flow Metab. 1994, 14, 251-261.
15. Gill, R.; Nordholm, L.; Lodge, D. The neuroprotective actions of 2,3-Dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline (NBQX) in a rat focal ischemia model. Brain Res. 1992, 580, 35-43.
16. Buchan, A. M.; Xue, D.; Huang, Z.-G.; Smith, K. H.; Lesiuk, H. Delayed AMPA receptor blockade reduces cerebral infarction induced by focal ischemia. NeuroReport 1991, 2, 473-476.
17. 1 neuronal injury. J. Cerebr. Blood Flow Metab. 1993, 15, 933-939.
18. Sheardown, M. J.; Suzdak, P. D.; Nordholm, L. AMPA, but not NMDA, receptor antagonism is neuroprotective in gerbil global ischemia even when delayed 24 h. Eur. J. Pharmacol. 1993, 236, 347-353.
19. Diemer, N. H; Jørgensen, M. B.; Johansen, F. F.; Sheardown, M. Honoré, T. Protection against ischemic hippocampal CA1 damage in the rat with a new non-NMDA antagonist, NBQX. Acta. Neurol. Scand. 1992, 86, 45-49.
20. Balchen, T.; Diemer, N. H. The AMPA antagonist, NBQX, protects against ischemia-induced loss of cerebellar Purkinje cells. Neuroreport 1992, 3, 785-788.
21. Le Peillet, E.; Arvin, B.; Moncada, C.; Meldrum, B. S. The non-NMDA antagonists, NBQX and GYKI 52466, protect against cortical and striatal cell loss following transient global ischaemia in the rat. Brain Res. 1992, 571, 115-120.
22. Buchan, A. M.; Lesiuk, H.; Barnes, K. A.; Li, H.; Huang, Z.-G.; Smith, K. E.; Xue, D. AMPA antagonists: do they hold more promise for clinical stroke trials than NMDA antagonists? Stroke [Suppl. 1] 1993, 24, I-148-I-152.
23. Pulsinelli, W.; Sarokin, A.; Buchan, A. Antagonism of the NMDA and non-NMDA receptors in global versus focal brain ischemia. In Progress in Brain Research; Kogure, K., Hossmann, K.-A., Siesjö, Eds.; Elsevier Science Publishers B. V.: Amsterdam, 1993; Vol. 96, pp 125-135.
24. Ohmori, J.; Sakamoto, S.; Kubota, H.; Shimizu-Sasamata, M.; Okada, M.; Kawasaki, S.; Hidaka, K.; Togami, J.; Furuya, T.; Murase, K. 6-(1H-Imidazol-1-yl)-7-nitro-2,3-(1H,4H)-quinoxalinedione hydrochloride (YM90K) and related compounds: structure-activity relationships for the AMPA-type non-NMDA receptor. J. Med. Chem. 1994, 37, 467-475.
25. Wätjen, F.; Nielsen, E.Ø.; Drejer, J.; Jensen, L. H. Isatin oximes - a novel series of bioavailable non-NMDA antagonists. BioMed. Chem. Lett. 1993, 3, 105-106.
26. 3H]kainate binding. Eur. J. Pharmacol. [mol. Pharmacol. Sect.] 1993, 246, 195-204.
27. Wätjen, F.; Bigge, C. F.; Jensen, L. H.; Boxer, P. A.; Lescosky, L. J.; Nielsen, E.Ø.; Malone, T. C.; Campbell, G. W.; Coughenour, L. J.; Rock, D. M.; Drejer, J.; Marcoux, F. NS 257 (1,2,3,6,7,8-hexahydro-3-(hydroxyimino)-N,N,7-trimethyl-2-oxobenzo[2,1-b: 3,4-c′]dipyrrole-5-sulfonamide) is a potent, systemically active AMPA receptor antagonist. BioMed. Chem. Lett. 1994, 4, 371-376.
28. Krogsgaard-Larsen, P.; Ferkany, J. W.; Nielsen, E. Ø.; Madsen, U.; Ebert, B.; Johansen, J. S.; Diemer, N. H.; Bruhn, T.; Beattie, D. T.; Curtis, D. R. Novel class of amino acid antagonists at non-N-methyl-D-aspartic acid excitatory amino acid receptors. Synthesis, in vitro and in vivo pharmacology, and neuroprotection. J. Med. Chem. 1991, 34, 123-130.
29. Hamilton, G. S.; Huang, Z.; Patch, R. J.; Guzewska, M. E.; Elliot, R. L.; Borosky, S. A.; Bednar, D. L.; Ferkany, J. W.; Karbon, E. W. Phsophonoethylphenylalanine derivatives as novel antagonists of non-NMDA ionotropic glutamate receptors. BioMed. Chem. Lett. 1992, 2, 1269-1274.
30. Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Lodge, D.; Leander, J. D.; Schoepp, D. D. 3SR,4aRS,6RS,8aRS-6-(2-(1H-Tetrazol-5-yl)ethyl)-decahydroisoquinoline-3- carboxylic acid: A structurally novel, systemically active, competitive AMPA receptor antagonist. J. Med. Chem. 1993, 36, 2046-2048.
31. Schoepp, D. D.; Lodge, D.; Bleakman, D.; Leander, J. D.; Tizzano, J. P.; Wright, R. A.; Palmer, A. J.; Salhoff, C. R.; Ornstein, P. L. In vitro and in vivo antagonism of AMPA receptor activation by 3S,4aR,6R,8aR-6-(2-(1H-tetrazol-5-yl)ethyl)decahydroisoquinoline-3-carboxylic acid. Neuropharmacology 1995, 34, 1159-1168.
32. Ornstein, P. L.; Schoepp, D. D.; Arnold, M. B.; Augenstein, N. K.; Lodge, D.; Millar, J. D.; Chambers, J. W.; Campbell, J.; Paschal, J. W.; Zimmerman, D. M. and Leander, J. D. 6-Substituted decahydroisoquinoline-3-carboxylic acids as potent and selective conformationally constrained NMDA receptor antagonists. J. Med. Chem. 1992, 35, 3547-3560.
33. Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Deeter, J. B.; Leander, J. D.; Lodge, D.; Calligaro, D. Ø.; Schoepp, D. D. Unusual stereochemical preferences of decahydroisoquinoline-3-carboxylic acid competitive NMDA antagonists. BioMed. Chem. Lett. 1993, 3, 2067-2072.
34. Bullock, R.; Graham, D. I.; Swanson, S.; McCulloch, J. Neuroprotective effect of the AMPA receptor antagonist LY293558 in focal cerebral ischemia in the cat. J. Cerebr. Blood Flow Metab. 1994, 14, 466-471.
35. Gill, R.; Lodge, D. The neuroprotective effects of the decahydroisoquinoline, LY 215490; a novel AMPA antagonist in focal ischemia. Neuropharmacology 1994, 33, 1529-1536.
36. Browne, S. E.; McCulloch, J. AMPA receptor antagonists and local cerebral glucose utilization in the cat. Brain Res. 1994, 647, 10-20.
37. Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Borromeo, P. S.; Lugar, C. W.; Leander, J. D.; Lodge, D.; Schoepp, D. D. Structure-activity studies of 6-substituted decahydroisoquinoline-3-carboxylic acid AMPA receptor antagonists. 2. Effects of distal acid bioisosteric substitution, absolute stereochemical preferences, and in vivo activity. J. Med. Chem. 1996, 39, 2232-2244.
38. Ornstein, P. L.; Augenstein, N. K.; Arnold, M. B. Stereoselective synthesis of 6-substituted decahyroisoquinoline-3-carboxylates: Intermediates for the preparation of conformationally constrained acidic amino acids. J. Org. Chem. 1994, 59, 7862-7869.
39. Ornstein, P. L.; Arnold, M. B.; Augenstein, N. K.; Paschal, J. W. Syntheses of 6-oxodecahydroisoquinoline-3-carboxylates. Useful intermediates for the preparation of conformationally defined excitatory amino acid antagonists. J. Org. Chem. 1991, 56, 4388-4392.
40. Ornstein, P. L.; Augenstein, N. K.; Arnold, M. B.; Leander, J. D.; Tizzano, J. P.; Lodge, D.; Schoepp, D. D. 3SR,4aRS,6SR,-8aRS-6-(1H-Tetrazol-5-yl)decahydroisoquinoline-3-carboxylic acid, a novel, competitive, systemically active NMDA and AMPA receptor antagonist. J. Med. Chem. 1995, 38, 4885-4890.
41. 3H]-CGS-19755: a novel N-methyl-D-aspartate antagonist with nanomolar affinity in rat brain. Br J. Pharmocol. 1988, 95, 932-938.
42. Nielsen, E. Ø.; Madsen, U.; Schaumburg, K.; Krogsgaard-Larsen, P. Studies on receptor-active conformations of excitatory amino acid agonists and antagonists. Eur. J. Med. Chem. Chim. Ther. 1986, 21, 433-437.
43. 3H]kainic acid, an analogue of L-glutamate. J. Neurochem. 1976, 26, 141-147.
44. Harrison, N. L.; Simmonds, M. A. Quantitative studies on some antagonists of N-methyl-D-aspartate in slices of rat cerebral cortex. Br. J. Pharmacol. 1985, 84, 381-391.
45. Ornstein, P. L.; Arnold, M. B.; Evrard, D.; Leander, J. D.; Lodge, D.; Schoepp, D. D. Tetrazole amino acids as competitive NMDA antagonists. BioMed. Chem. Lett. 1993, 3, 43-48.
46. Ornstein P. L.; Schoepp, D. D.; Arnold, M. B.; Leander, J. D.; Lodge, D.; Paschal, J. W.; Elzey, T. 4-(Tetrazolylalkyl)piperidine-2-carboxylic acids. Potent and selective N-methyl-D-aspartic acid receptor antagonists with a short duration of action. J. Med. Chem. 1991, 34, 90-97.
47. Whitten, J. P.; Baron, B. M.; Muench, D.; Miller, F.; White, H. S.; McDonald, I. A. (A)-4-Oxo-5-phosphononorvaline: a new competitive glutamate antagonist at the NMDA receptor complex. J. Med. Chem. 1990, 33, 2961-2963.
48. Whitten, J. P.; Muench, D.; Cube, R. W.; Nyce, P. L.; Baron, B. M.; McDonald, I.A. Synthesis of 3-(S)-phosphonoacetyl-2-(R)-piperidinecarboxylic acid, a conformationally-restricted glutamate antagonist. BioMed. Chem. Lett. 1991, 1, 441-444.
49. Claesson, A.; Swahn, B.-M.; Edvinsson, K. M.; Molin, H.; Sandberg, M. Competitive NMDA antagonists that base their activity on a unique conformational effect. BioMed. Chem. Lett. 1992, 2, 1247-1250.
50. Evans, R. H.; Francis, A. A.; Jones, A. W.; Smith, D. A. S.; Watkins, J. C. The effects of a series of ω-phosphonic α-carboxylic amino acids on electrically evoked and excitant amino acid-induced responses in isolated spinal cord preparations. Br. J. Pharmacol. 1982, 75, 65-75.
51. Baudy, R. B.; Greenblatt, L. P.; Jirkovsky, I. L.; Conklin, M.; Russo, R. J.; Bramlett, D. R.; Emrey, T. A.; Simmonds, J. T.; Kowal, D. M.; Stein, R. P.; Tasse, R. P. Potent quinoxaline-spaced phosphono α-amino acids of the AP-6 type as competitive NMDA antagonists: synthesis and biological evaluation. J. Med. Chem. 1993, 36, 331-342.